Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | NPM1 | P06748 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | PRKACG | P22612 | 1/20 | 0.43 |
| ▸ | PRKACB | P22694 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20604669 | 0.92 | MEN1 (0.57) | HTTLMNAPOLBCYP19A1MAPT | |
| SCHEMBL20604603 | 0.89 | CYP19A1 (0.46) | HTTLMNACYP11B1CYP11B2POLB | |
| SCHEMBL15585968 | 0.88 | CHRNB2 (0.46) | HTTLMNAPOLBCYP19A1SMN1; SMN2 | |
| SCHEMBL20604670 | 0.87 | ALDH1A1 (0.48) | HTTLMNACYP11B1CYP11B2POLB | |
| SCHEMBL20604674 | 0.84 | LMNA (0.40) | HTTLMNAPOLBCYP19A1MAPT | |
| SCHEMBL20604653 | 0.83 | MAPK10 (0.51) | HTTLMNACYP11B1CYP11B2POLB | |
| SCHEMBL20604637 | 0.82 | APP (0.52) | HTTCYP11B1CYP11B2CYP19A1KMT2A | |
| SCHEMBL20604702 | 0.80 | LPO (0.45) | HTTLMNAPOLBMAPTKMT2A | |
| SCHEMBL22359809 | 0.79 | ALDH1A1 (0.45) | HTTLMNACYP11B1CYP11B2CYP19A1 | |
| SCHEMBL4856398 | 0.78 | CYP11B1 (0.53) | HTTLMNACYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423443-B1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2020-08-19 | — | — | EP | disclosed |
| US-10590079-B2 | Cyano-substituted indoles as LSD1 inhibitors | NOVARTIS AG (CH) | 2020-03-17 | — | — | US | disclosed |
| US-20190092724-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2019-03-28 | — | — | US | disclosed |
| US-20190092724-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2019-03-28 | — | — | US | disclosed |
| EP-3423443-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | Novartis AG (CH) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590079-B2 | Cyano-substituted indoles as LSD1 inhibitors | KDM1A, KDM1B, KDM3A | HTT 2676/4885LMNA 1584/4885CYP11B1 610/4885 |
| US-20190092724-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM2A | HTT 2919/4885LMNA 1435/4885CYP11B1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.